Protara Therapeutics, Inc., a clinical-stage biotechnology company focused on cancer and rare diseases, has received multiple regulatory boosts from the U.S. Food and Drug Administration (FDA) for its investigational therapy TARA-002. The FDA has granted both Breakthrough Therapy and Fast Track designations to the cell-based therapy for the treatment of pediatric patients with macrocystic and mixed cystic lymphatic malformations (LMs), rare vascular disorders that can cause significant morbidity in children.
In addition to the expedited development designations, the FDA has selected TARA-002 to participate in the Chemistry, Manufacturing, and Controls (CMC) Development and Readiness Pilot (CDRP) Program. The initiative is designed to support therapies with accelerated clinical development timelines by strengthening early collaboration between sponsors and regulators on manufacturing and quality strategies, ultimately aiming to provide patients with earlier access to promising treatments.
Lymphatic malformations are uncommon, often congenital conditions characterized by abnormal development of the lymphatic system. Current treatment options are limited and may involve invasive procedures or repeated interventions, highlighting the unmet medical need in pediatric patients. The FDA’s decision reflects preliminary clinical evidence suggesting that TARA-002 could offer meaningful improvement over existing approaches.
Breakthrough Therapy designation is reserved for drug or biologic candidates intended to treat serious or life-threatening conditions where early clinical data indicate the potential for substantial benefit on clinically significant endpoints. Fast Track designation, meanwhile, is intended to facilitate development and speed regulatory review for therapies addressing serious diseases with unmet medical needs. Together, these designations allow for more frequent interaction with the FDA and the possibility of a more streamlined path to approval.
Protara’s chief executive officer, Jesse Shefferman, said the designations underscore both the urgent need for new treatments for pediatric LMs and the company’s confidence in TARA-002’s potential. He added that Protara plans to engage with the FDA in the first half of the year to define the regulatory pathway toward registration for the therapy in this indication.
TARA-002 had previously received Rare Pediatric Disease designation for lymphatic malformations, further emphasizing its relevance to a small and underserved patient population. Participation in the CDRP Program will support the therapy’s manufacturing and quality development not only for the LM indication but also for Protara’s non-muscle invasive bladder cancer (NMIBC) program.
With these regulatory milestones, Protara strengthens the development outlook for TARA-002 and moves closer to potentially delivering a new therapeutic option for children affected by lymphatic malformations, while also advancing its broader pipeline of innovative treatments.